Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05761951 |
Title | Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer |
Recruitment | Recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | Yes |
Sponsors | M.D. Anderson Cancer Center |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |